Does chronic oral contraceptive use detrimentally affect C-reactive protein or iron status for endurance-trained women?

Loading...
Thumbnail Image

DOI

Open Access Location

Journal Title

Journal ISSN

Volume Title

Publisher

Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.

Rights

(c) 2023 The Author/s
CC BY 4.0

Abstract

PURPOSE: Chronic use of the oral contraceptive pill (OCP) is reported to increase C-reactive protein (CRP) levels and increase the risk of cardiovascular disease in premenopausal females. METHODS: A secondary analysis of data from two research studies in eumenorrheic (n = 8) and OCP (n = 8) female athletes. Basal CRP and iron parameters were included in the analysis. Sample collection occurred following a standardized exercise and nutritional control for 24 h. Eumenorrheic females were tested in the early-follicular and mid-luteal phases, and the OCP users were tested in quasi-follicular and quasi-luteal phases (both active pill periods). RESULTS: A main effect for group (p < 0.01) indicated that average CRP concentration was higher in OCP users compared with eumenorrheic females, regardless of the day of measurement within the cycle. Results demonstrate a degree of iron parameters moderation throughout the menstrual cycle that is influenced by basal CRP levels; however, no linear relationship with CRP, serum iron, and ferritin was observed. CONCLUSIONS: Basal CRP values were consistently higher in the OCP group despite participants being in a rested state. These results may indicate a potential risk of cardiovascular disease in prolonged users of the OCP when compared to eumenorrheic female athletes.

Description

Citation

Badenhorst CE, Govus AD, Mündel T. (2023). Does chronic oral contraceptive use detrimentally affect C-reactive protein or iron status for endurance-trained women?. Physiol Rep. 11. 14. (pp. e15777-).

Collections

Endorsement

Review

Supplemented By

Referenced By

Creative Commons license

Except where otherwised noted, this item's license is described as (c) 2023 The Author/s